{
  "id": "Asymptomatic_Myeloma_Prognosis.v0",
  "gdl_version": "2.0",
  "concept": "gt0001",
  "language": {
    "original_language": "ISO_639-1::en"
  },
  "description": {
    "original_author": {
      "date": "2020-02-23",
      "name": "Jack Msonkho",
      "organisation": "Cambio CDS",
      "email": "models@cambiocds.com"
    },
    "lifecycle_state": "Not set",
    "details": {
      "en": {
        "id": "en",
        "purpose": "Predicts risk of progression of asymptomatic (smoldering) multiple myeloma to active myeloma or amyloidosis.\n",
        "keywords": [
          "Myeloma",
          "Amyloidosis"
        ],
        "use": "Newly diagnosed multiple myeloma (MM) patients meeting International Myeloma Working Group criteria for smoldering or asymptomatic MM (see Pearls/Pitfalls for criteria).\n\nProvides prognostic information for patients.\nSuggests patients who may need closer follow up.\nAllows for stratification of patients on clinical trials potentially evaluating newer, targeted myeloma therapies.\nDoes not require FISH studies, cytogenetic, or MRI bone studies, which may add further discrimination but are not widely available; hence, generalizability is preserved in settings with limited availability of these studies.\n",
        "copyright": "@Cambio CDS"
      }
    },
    "other_details": {
      "references": "Clinical course and prognosis of smoldering (asymptomatic) multiple myeloma.\nRobert A Kyle;Ellen D Remstein;Terry M Therneau;Angela Dispenzieri;Paul J Kurtin;Janice M Hodnefield;Dirk R Larson;Matthew F Plevak;Diane F Jelinek;Rafael Fonseca;Lee Joseph Melton;S Vincent Rajkumar\nISSN: 0028-4793 , 1533-4406; DOI: 10.1056/NEJMoa070389\nThe New England journal of medicine. , 2007, Vol.356(25), p.2582-2590"
    }
  },
  "definition": {
    "data_bindings": {
      "gt0002": {
        "id": "gt0002",
        "model_id": "openEHR-EHR-OBSERVATION.asymptomatic_myeloma_prognosis.v0",
        "template_id": "openEHR-EHR-OBSERVATION.asymptomatic_myeloma_prognosis.v0",
        "type": "INPUT",
        "elements": {
          "gt0003": {
            "id": "gt0003",
            "path": "/data[at0001]/events[at0002]/data[at0003]/items[at0004]"
          },
          "gt0004": {
            "id": "gt0004",
            "path": "/data[at0001]/events[at0002]/data[at0003]/items[at0006]"
          }
        }
      },
      "gt0005": {
        "id": "gt0005",
        "model_id": "openEHR-EHR-EVALUATION.asymptomatic_myeloma_prognosis.v0",
        "template_id": "openEHR-EHR-EVALUATION.asymptomatic_myeloma_prognosis.v0",
        "type": "OUTPUT",
        "elements": {
          "gt0006": {
            "id": "gt0006",
            "path": "/data[at0001]/items[at0002]"
          }
        }
      }
    },
    "rules": {
      "gt0007": {
        "id": "gt0007",
        "priority": 3,
        "when": [
          "$gt0003|Bone marrow plasmacytosis|==1|local::at0007|<10% |",
          "$gt0004|Serum monoclonal protein, g/dL|==0|local::at0008| ≥3 g/dL|"
        ],
        "then": [
          "$gt0006|Risk Level|=0|local::at0003|Low risk|"
        ]
      },
      "gt0008": {
        "id": "gt0008",
        "priority": 2,
        "when": [
          "$gt0003|Bone marrow plasmacytosis|==0|local::at0005| ≥10% |",
          "$gt0004|Serum monoclonal protein, g/dL|==1|local::at0009|<3 g/dL|"
        ],
        "then": [
          "$gt0006|Risk Level|=1|local::at0004|Intermediate risk|"
        ]
      },
      "gt0009": {
        "id": "gt0009",
        "priority": 1,
        "when": [
          "$gt0003|Bone marrow plasmacytosis|==0|local::at0005| ≥10% |",
          "$gt0004|Serum monoclonal protein, g/dL|==0|local::at0008| ≥3 g/dL|"
        ],
        "then": [
          "$gt0006|Risk Level|=2|local::at0005|High risk|"
        ]
      }
    }
  },
  "ontology": {
    "term_definitions": {
      "en": {
        "id": "en",
        "terms": {
          "gt0001": {
            "id": "gt0001",
            "text": "Asymptomatic Myeloma Prognosis",
            "description": "Predicts risk of progression of asymptomatic (smoldering) multiple myeloma to active myeloma or amyloidosis.\n"
          },
          "gt0003": {
            "id": "gt0003",
            "text": "Bone marrow plasmacytosis",
            "description": "*"
          },
          "gt0004": {
            "id": "gt0004",
            "text": "Serum monoclonal protein, g/dL",
            "description": "*"
          },
          "gt0006": {
            "id": "gt0006",
            "text": "Risk Level",
            "description": "*"
          },
          "gt0007": {
            "id": "gt0007",
            "text": "Low Risk"
          },
          "gt0008": {
            "id": "gt0008",
            "text": "Intermediate Risk"
          },
          "gt0009": {
            "id": "gt0009",
            "text": "High Risk"
          }
        }
      }
    }
  }
}